As for nonvalvular atrial fibrillation (NVAF) patients with left atrial thrombus or spontaneous echo contrast (LAT/SEC), we evaluated the additional predictive value of serum uric acid (SUA) and Left atrial diameter (LAD) for CHADS2 and CHA2DS2-VASc, and explored the influence from the level of SUA and LAD to LAT/ SEC in moderate risk group. Thus, we put forward the concept of a borderline high risk group to guide clinical anticoagulant therapy in patients with NVAF.
A trial fibrillation (AF) is the most common arrhythmia, affecting approximately 8 million patients in China. 1) Meanwhile, its morbidity is increasing with the aging population as well as the morbidity of cardiovascular disease year by year. Cardiac stroke accounted for about a quarter of all patients with stroke, and more than half of them were caused by AF. 2) AF increased the risk of stroke by five times. Among them, more than 90% of embolism comes from left atrial appendage (LAA). Therefore, preventing thrombus in LAA can reduce the morbidity of stroke, and it can be used as a substitute to prevent patients with AF from stroke in earlier stage.
At present, CHADS2 scores and CHA2DS2-VASc scores are widely accepted and practical clinical stroke risk stratifications. Recently, some researches have shown that CHADS2 and CHA2DS2-VASc scores not only predict stroke risk, but also have an obvious relationship with LAT and can be used to predict the formation of LAT. [3] [4] [5] [6] However, Yarmohammadi, et al. 4) found that patients with a score of 0 or 1 point in CHADS2 accounted for almost a third of the total with atrial thrombus. In addition, a prospective study including 295 NVAF patients with 0 or 1 point CHADS2 score were followed up, onaverage for 5 years. The results showed that 3% of the patients had LAT and 8% of patients had SEC. 7) By adding some additional risk factors to CHADS2 and CHA2DS2-VASc score, especially in patients who should have anticoagulant therapy but were ignored, the stroke risk in NVAF patients can be determined at an earlier stage. 8, 9) Recently, some researches have showed that SUA and LAD were risk factors of LAT/SEC, 3, 7, [10] [11] [12] so this study was aimed to explore the additional predictive value of SUA and LAD to CHADS2 and CHA2DS2-VASc score in NVAF patients. We then explored the influence from SUA and LAD of patients who are 0 or 1 point in CHADS2 or CHA2DS2-VASc score. Meanwhile, we proposed the concept of borderline high risk group to guide the clinical anticoagulant therapy in NVAF patients.
Methods

Study population:
We retrospectively chose 284 consecutive patients with NVAF from January 1, 2011 to March 31, 2016 in the First Hospital of China Medical University. The exclusive criteria included: 1) hypertrophic cardiomyopathy; 2) congenital heart disease; 3) history of infective endocarditis or rheumatic heart disease; 4) history of hyperthyroidism; 5) sleep apnea hypopnea syndrome; 6) valve anomalies, such as severe valvular stenosis and mitral valve prolapse syndrome; 7) history of heart surgery, such as coronary artery bypass graft, valvuloplasty and valve replacement; 8) end-stage renal dysfunction[estimated glomerular filtration rate [(eGFR) < 15 mL/(minute × 1.73 m 2 )]. In addition, the history of anticoagulant therapy can prevent the formation of LAT in a certain extent, so it was also listed in the exclusive criteria. Clinical data: The clinical data we collected included stroke risk factors, serological indexes, echocardiograph indexes, history of antiplatelet, history of smoking and drinking, classification of NYHA (New York Heart Association), types of AF, CHADS2 (a total of 6 points) and CHA2DS2-VASc (a total of 9 points). One point was assigned for the history of congestive heart failure (CHF), hypertension (HT), diabetes mellitus (DM) or age ("75 years) in CHADS2 score; whereas it was assigned for females, between 65 and 74 years of age, history of CHF, HT, DM and vascular disease in CHA2DS2-VASc score. Two points were in the condition for history of stroke, transient ischemic attack (TIA) or thromboembolism (TE) in CHADS2 score and the history of stroke, TIA or TE as well as age ("75 years) in CHA2DS2-VASc score. Among them, CHF referred to the clinical diagnosis, NYHA II + or LVEF (Left Ventricular Ejection Fraction) (!40%) and vascular disease included prior myocardial infarction, complex aortic plaques and peripheral vascular disease. The diagnosis of AF: All selected patients were NVAF confirmed by TEE or transthoracic echocardiography (TTE), without the history of rheumatic mitral stenosis, a mechanical or bioprosthemic heart valve replacement or mitral valvoplasty. The clinical diagnosis of AF was made with respect to the AHA/ACC/HRS guideline for the management of patients with AF in 2006, 13) updated in 2011 14) and 2014. 15) The process of clinical diagnosis was completed with more than two experienced doctors working in our hospital, according to episodes of AF in routine 12lead electrocardiogram (ECG) or 24 hours ECG Holter monitoring at least once or the clear history of AF. Evaluation by TTE and TEE: TEE was the gold standard in the diagnosis of LAT. All selected patients in the hospital took TEE in order to make clear whether existing LAT/SEC or not by Phillip iE33 color doppler ultrasonic diagnostic instrument and S5-1 probe at the frequency of 1-5 MHZ. Thrombus in LAA was defined as an echodense mass attached to the LAA wall that could be distinguished from the LA or LAA endocardium and the pectinate muscles in more than one imaging plane. 16 ) SEC referred to the dynamic "smoke-like" echoes with the characteristic swirling motion in optimal gain setting during the entire cardiac cycle. 17) The operations and diagnosis of LAT/SEC were corporately completed with two experi-enced ultrasonic technicians working in our hospital according to the guidelines for TEE recommended from American Society of Echocardiography (ASE) and the Society of Cardiovascular Anesthesiologists in 1999, 18) updated in 2013. 19) Inconsistent diagnoses were resolved by a third technician.
In 28 patients with LAT, we lost contact with 2 patients. 17 (65.5%) patients reviewed TEE after 1 to 20 months in the remaining 26 patients. Consequently, there are 7 patients still retaining LAT even now. During follow-up of 26 patients, thromboembolic events happened in 6 patients (one person had lower limb artery embolization and 5 had cerebral infarction). In addition, one patient died of cerebral infarction.
All patients had taken TTE before TEE by a Phillip iE33 color doppler ultrasonic diagnostic instrument with a X7-2t probe at a frequency of 2 MHZ. The instrument was operated by more than two experienced ultrasound technicians working in our hospital with respect of the ASE's guidelines from 2005 20) and its update in 2015. 21) Statistics analysis: We used statistical software SPSS17.0 for statistical analysis. Continuous data were expressed as mean ± standard deviation and normal distribution was tested by Kolmogolov-Smirnov test. We performed Student's t-test or Mann-Whitney U test to compare two groups. Categorical data were counted as number and percentage, with comparison performed by the Pearson chisquare test, categorical variables chi-square test, or Fisher's exact test, between two groups. We analyzed the relationship between CHADS2/CHA2DS2-VAS and LAT/ SEC by trend chi-square test.
Binary Logistic regression analysis was used to explore independent risk factors of LAT/SEC. The area under the curve (AUC) in the receiver operating characteristic (ROC) was an proper substitute for the predictive value of the indexes to LAT/SEC. We compared their AUCs by MedCalc software. Among them, the largest Youden index was regarded as the optimal cut-off value to predict LAT/ SEC (Youden index = sensitivity + specificity -1).
Results
The comparison of baseline characteristics between the study populations for two groups:
The study population consisted of 284 patients with an average age of 60.40 ± 9.96 years old and 37.7% of them were female. The comparison of baseline characteristics between the study populations for two groups were shown in Table I .
Compared with No LAT/SEC group, the proportions of patients with CHF (23.0% versus 3.1%, P < 0.001), HT (65.6% versus 47.1%, P = 0.014), prior stroke/TIA/ TE (18.0% versus 5.4%, P = 0.003), vascular disease (14.8% versus 5.8%, P = 0.030) and NYHA II + (21.3% versus 3.1%, P < 0.001) in LAT/SEC group were significantly increased, while the proportions of people with DM, female, smoking, drinking and the history of antiplatelet therapy between two groups had no obvious differences.
In serological indexes, BNP (212.80 ± 204.47 versus 125.30 ± 164.30, P < 0.001) and SUA (384.97 ± 85.94 versus 331.16 ± 93.34, P < 0.001) in LAT/SEC group SUA, LAD, LAT/SEC AND NVAF 36 .1% and 37.7%) for CHADS2 score. However, the proportions of patients in different risk groups both gradually rose followed by the risen risk stratification of stroke in both groups.
In order assess to the relationship of the study between CHADS2/CHA2DS2-VASc score and LAT/SEC better, we calculated the proportions of LAT/SEC in risk stratification of CHADS2 and CHA2DS2-VASc score (Figures 1A, 1B) . With the increase of stroke risk stratification, the proportions of LAT/SEC in CHADS2 and CHA2 DS2-VASc also gradually rose (14.7 versus 20.4 versus 34.3, P = 0.003; 14.3 versus 16.9 versus 27.3, P = 0.024). The independent risk factors of LAT/SEC: After adjusted stroke risk factors (such as age, gender, CHF, HT, DM, vascular disease and prior stroke/TIA/TE), and history of antiplatelet therapy, we found that only LAD and SUA were the independent risk factors of LAT/SEC (OR 1.109, 95% CI 1.033-1.191, P = 0.004; OR 1.005, 95%CI 1.001-1.009, P = 0.026). (Table II) will be inserted here in the next step. Please confirm it.
Ning, ET AL The predictive ability of serological and echocardiographic indexes to LAT/SEC: The predictive ability of serological and echocardiographic indexes to LAT/SEC by the analysis of ROC and the results were shown in Table III. As SUA, LAD and LVEDD were greatly influenced by gender, we divided the above indicators into two groups according to gender. After the analysis of ROC, SUA (female) and LAD had moderate predictive power for LAT/SEC while the predictive ability of SUA (men), LVEDD and BNP for LAT/SEC were poorer. Moreover, eGFR, HDL-C and LVEF had not predictive ability for LAT/SEC. By calculating Youden index, we found the op-SUA, LAD, LAT/SEC AND NVAF Table IV . The predictive abilities of CHADS2 and CHA2DS2-VASc were enhanced after being added with related factors. Among them, the AUCs of CHADS2-LAD-SUA and CHA2DS2-VASc-LAD-SUA were largest. After comparison of ROC curves, we found that CHADS2-LAD-SUA had the higher predictive value of LAT/SEC than CHADS2-LAD (P** = 0.006) and CHADS 2-BNP (P = 0.002). Meanwhile, CHA2DS2-VASc-LAD-SUA had the higher predictive value of LAT/SEC than CHADS2-VASc-LAD (P** = 0.001) and CHADS2-VASc-BNP (P = 0.005).
The influence from SUA and LAD to LAT/SEC in different risk stratification of stroke: Then patients were divided into three groups according to the risk stratification of CHADS2/CHA2DS2-VASc and compared with CHADS2-LAD-SUA/CHA2DS2-VASc-LAD-SUA respectively ( Figures 3A, 3B, 4A, 4B) . The number of patients with 0 points decreased by 43.12% and 51.79% for CHADS2 and CHA2DS2-VASc after being added with SUA and LAD. Among them, the proportion of LAT/SEC decreased by 50% and 37.8%. Compared to the CHADS2 and CHA2DS2-VASc, the number of patients in high risk group increased by 122.39% and 39.57% after being added with SUA and LAD.
In different risk stratifications of CHADS2 and CHA2 DS2-VASc score, the effect from levels of SUA/LAD to LAT/SEC were shown in Table V. In the moderate risk group, when the level of SUA or LAD was larger than optimal cut-off values, their incidence rates of LAT/SEC were significant higher than those in opposite conditions (27.8 versus 5.6, P = 0.006; 24.0 versus 7.7, P = 0.037). The same condition occurred to the high risk group of Ning, ET AL SUA, LAD, LAT/SEC AND NVAF CHADS2 and CHA2DS2-VASc score (51.0 versus 0, P < 0.001; 42.4 versus 3.7, P < 0.001). However, there was no significant effect of SUA/LAD to the incidence rate of LAT/SEC in low risk group.
Discussion
Recently, some studies have confirmed that LAT was associated with an increased risk of thromboembolic events in AF patients. [22] [23] [24] [25] It occurred to AF patients with LAT that half of them still had cerebral infarction and death after following up 3 years despite of having anticoagulation. 22) LAT, as the main embolus for cardiac stroke, can be used as alternative indicator of early prevention from stroke in patients with AF.
In our study, the proportion of LAT/SEC gradually increased with the risk stratification heightening. Whereas, there were still LAT/SEC in 14.7% and 20.4% of patients for low risk and moderate risk group in CHADS2, as well as 14.3% and 16.9% in CHA2DS2-VASc. Therefore, CHADS2 and CHA2DS2-VASc still have certain limitations in predicting LAT/SEC. Based on this, it is necessary to add some serological or echocardiographic indexes to them.
Enlarged LAD is common in the examination of TTE for AF patients. A study included 582 patients with AF showed that up to 86.2% of patients had increased LAD and proved that CHADS2 and CHA2DS2-VASc score increased with increased LAD. 12) At the same time, Kleemann, et al. 7) found that LAD > 50 mm was an independent risk factor of LAT and dense SEC by following up NVAF patients with 0 or 1 points in CHADS2 score. Our study also proved that LAD was the independent risk factor for LAT/SEC and had the moderate predictive value for LAT/SEC (AUC 0.731 in male, AUC 0.743 in female).
SUA, as a byproduct from purine catabolism, is produced by the catalysis of xanthine oxidase in the end. Recently, some research has shown that SUA was related with AF. 26, 27) The atherosclerosis risk in communities (ARIC) study showed that SUA was the risk factor of the incidence rate of AF. 27) In addition, some studies suggested that SUA was associated with the formation of atrial thrombus. 9, 10) A study which included 1354 patients with NVAF in the Guang Dong General Hospital proved that SUA was the independent risk factor for the formation of the SEC (OR: 1.008, P < 0.001). In the southern region of China, SUA had a moderate predictive value for SEC in LA. 9) Another study which included 1359 patients with NVAF also confirmed the SUA had the independent positive correlation with LAT (OR 1.004, P = 0.028). 10) At present, the mechanism of SUA to promote the incidence of AF and the formation of thrombus remains unclear. However, promoting atrial oxidative stress and inflammatory response was thought to be basis. 28, 29) Increased SUA was mainly caused by increased decomposition of purine due to tissular hypoxia and cellular apoptosis, which produced more active oxygen. 30) Active oxygen could produce oxidative stress to cardiac intima, and thus SUA could be used as the marker of cardiac oxidative stress, 31, 32) which could be the basis of atrial thrombosis. At the same time, SUA could also promote tissular in-flammation, which was thought to increase the possibility of atrial thrombus. 33) So far, both ionic channel and structural remodeling caused by hyperuricemia might be plausible explanations for the occurrence of AF. 34) In addition, SUA was associated with HT, CHF, DM and vascular disease, which indirectly promoted the formation of the atrial thrombus. 35, 36) In our study, SUA was an independent predictor of LAT/SEC and the predictive ability of CHADS2 and CHA2DS2-VASc increased after being added with SUA.
Considering that SUA and LAD were both the independent predictors of LAT/SEC, we added SUA and LAD to CHADS2 and CHA2DS2-VASc score. The results showed that the predictive abilities of CHADS2 and CHA2 DS2-VASc were enhanced after being combined with them. After comparison of ROC curves between new scoring systems, we could got that CHADS2-LAD-SUA and CHA2DS2-VASc-LAD-SUA had the higher predictive value of LAT/SEC.
We then did further study on the influence from SUA and LAD to LAT/SEC in the risk stratification of stroke. The number of patients with 0 points decreased by 43.12% and 51.79% for CHADS2 and CHA2DS2-VASc after being added with SUA and LAD. Among them, the proportion of LAT/SEC decreased by 50% and 37.8%. Patients in low risk group transferred to moderate risk and high risk groups, which could downgrade the proportion of patients with necessity to have anticoagulant therapy, but being neglected could upgrade the compliance of patients to take anticoagulants. For people whose CHADS2 and CHA2DS2-VASc score were 1 point, 2014 AHA/ACC/ HRS Guideline 15) recommended them to have anticoagulation therapy, antiplatelet therapy or no antithrombotic therapy. However, our research showed that the incidence of LAT/SEC significantly increased when SUA or LAD was higher than optimal cut-off value (27.8 versus 5.6, P = 0.006; 24.0 versus 7.7, P = 0.037). Therefore, this study proposed the new concept, named borderline high risk group, in the condition that patients had one point in CHADS2 or CHA2DS2-VASc, accompanied that SUA or LAD was higher than cut-off values. As for this condition, we recommend them to have anticoagulant therapy, which could prevent the formation of LAT/SEC in a certain extent. Study limitations: At first, this research mainly included the crowd who took TEE examination for radiofrequency ablation, which cannot reflect the true condition of the crowd. Secondly, atrial thrombus, as main alternative indicators of cardiac stroke, cannot fully represent clinical thromboembolic events. Finally, this study only followed up the left atrial thrombus group and was unable to fully embody the prognosis of atrial thrombus because of the small sample sizes. Therefore, it still needs more clinical prospective researches in this area.
Conclusions
SUA and LAD were both the independent risk factors of the formation of LAT/SEC and increased the predictive ability of CHADS2 and CHA2DS2-VASc for LAT/ SEC as additional factors. For patients in moderate risk group of CHADS2 and CHA2DS2-VASc score, if SUA or LAD was higher than optimal cut-off values in different sexes, the risk of thromboembolism events would rise accompanied by the elevated risk of LAT/SEC.
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